Prostate Specific Antigen and Bone Scan Correlation in the Staging and Monitoring of Patients with Prostatic Cancer

1992 ◽  
Vol 70 (3) ◽  
pp. 295-298 ◽  
Author(s):  
P. D. MILLER ◽  
I. EARDLEY ◽  
R. S. KIRBY
Tumor Biology ◽  
1990 ◽  
Vol 11 (6) ◽  
pp. 289-294 ◽  
Author(s):  
X. Filella ◽  
R. Molina ◽  
J. Jo ◽  
B. Umbert ◽  
J.L. Bedini ◽  
...  

2005 ◽  
Vol 23 (9) ◽  
pp. 1962-1968 ◽  
Author(s):  
Zohar A Dotan ◽  
Fernando J. Bianco ◽  
Farhang Rabbani ◽  
James A. Eastham ◽  
Paul Fearn ◽  
...  

Purpose Physicians often order periodic bone scans (BS) to check for metastases in patients with an increasing prostate-specific antigen (PSA; biochemical recurrence [BCR]) after radical prostatectomy (RP), but most scans are negative. We studied patient characteristics to build a predictive model for a positive scan. Patients and Methods From our prostate cancer database we identified all patients with detectable PSA after RP. We analyzed the following features at the time of each bone scan for association with a positive BS: preoperative PSA, time to BCR, pathologic findings of the RP, PSA before the BS (trigger PSA), PSA kinetics (PSA doubling time, PSA slope, and PSA velocity), and time from BCR to BS. The results were incorporated into a predictive model. Results There were 414 BS performed in 239 patients with BCR and no history of androgen deprivation therapy. Only 60 (14.5%) were positive for metastases. In univariate analysis, preoperative PSA (P = .04), seminal vesicle invasion (P = .02), PSA velocity (P < .001), and trigger PSA (P < .001) predicted a positive BS. In multivariate analysis, only PSA slope (odds ratio [OR], 2.71; P = .03), PSA velocity (OR, 0.93; P = .003), and trigger PSA (OR, 1.022; P < .001) predicted a positive BS. A nomogram for predicting the bone scan result was constructed with an overfit-corrected concordance index of 0.93. Conclusion Trigger PSA, PSA velocity, and slope were associated with a positive BS. A highly discriminating nomogram can be used to select patients according to their risk for a positive scan. Omitting scans in low-risk patients could reduce substantially the number of scans ordered.


1990 ◽  
Vol 8 (11) ◽  
pp. 1830-1838 ◽  
Author(s):  
H I Scher ◽  
T Curley ◽  
N Geller ◽  
C Engstrom ◽  
D D Dershaw ◽  
...  

Thirty-one patients with bidimensionally measurable hormone-refractory prostatic cancer received trimetrexate (TMTX). Serial values of prostate-specific antigen (PSA) and acid phosphatase (SAP) were correlated with response. Five patients (17%; 95% confidence interval, 3% to 30%) achieved a partial remission for a median of 3 months (range, 3 to 7.5 months). Marker levels showed large variations with no discernible patterns. Serial PSA and SAP in 19 patients with abnormal baseline values showed a correlation with measurable disease response in only 68% (13 of 19) and 47% (nine of 19) of patients, respectively. Values were then smoothed using an exploratory data analysis technique of running medians and averages. Trends in marker changes were much more apparent. Several "decision rules" were evaluated for use of markers as indices of disease progression. A 50% increase from the patient's minimum value in either PSA or SAP on two successive determinations correlated with progression in 90% of cases in this trial. TMTX has modest activity in prostatic cancer, and further trials are not warranted. Biochemical markers do not uniformly reflect disease activity in hormone-refractory disease, and changes in biochemical markers must be interpreted cautiously when used as the sole end point to assess efficacy in clinical trials.


1996 ◽  
Vol 5 (1) ◽  
pp. 25-31 ◽  
Author(s):  
Khalda Al-Zaabi ◽  
Mahmoud Tuli ◽  
Shawkatc Jahan ◽  
Shibab Al-Mohannadi ◽  
Mohammad Naem ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document